The Potential Benefits and Controversies of Probiotics Use in Patients at Different Stages of Chronic Kidney Disease

• Published in: Nutrients 2022-09, Vol.14 (19), p.4044
• Main Authors: Tian, Na, Li, Lu, Ng, Jack Kit-Chung, Li, Philip Kam-Tao
• Format: Article
• Language: English
• Subjects: Amino acids; Atherosclerosis; Bacteria; Cardiovascular diseases; chronic kidney disease; Chronic kidney failure; Clinical trials; Colon; Development and progression; Dialysis; Diet; Diet therapy; Digestive system; Fatty acids; Fruits; Gastrointestinal symptoms; Gastrointestinal system; gut dysbiosis; Health aspects; Health risks; Hemodialysis; Inflammation; Intestinal microflora; Kidney diseases; Kidneys; Metabolism; Metabolites; Microbiomes; Microbiota; Microbiota (Symbiotic organisms); Microorganisms; Patients; Peritoneal dialysis; Physiological aspects; Prebiotics; Probiotics; Quality of life; Renal failure; Review; Risk management; Toxins; Vegetables; Vegetarianism
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu14194044

The therapeutic modulation of the gut microbiome has been suggested to be one of the tools in the integrated management of chronic kidney disease (CKD) in recent years. Lactobacillus and Bifidobacterium genera are the two most commonly used probiotics strains. Most of the probiotics used in studies are mixed formulation. There is no consensus on the dose and duration of the probiotic administration for CKD patients Increasing evidence indicates that patients with early stage (1–2) CKD have an altered quantitative and qualitative microbiota profile. However, there was a dearth of prospective controlled studies on the use of probiotics in the early stage of the CKD population. The association between gut microbiota disturbance and advanced CKD was reported. Most randomized controlled trials on probiotic treatment used in CKD stage 3–5ND patients reported positive results. The metabolites of abnormal gut microbiota are directly involved in the pathogenetic mechanisms of cardiovascular disease and inflammation. We summarized 13 studies performed in the dialysis population, including 10 in hemodialysis (HD) patients and 3 in peritoneal dialysis (PD). Some controversial results were concluded on the decreasing plasma concentration of uremic toxin, symptoms, inflammation, and cardiovascular risk. Only three randomized controlled trials on PD were reported to show the potential beneficial effects of probiotics on inflammation, uremic toxins and gastrointestinal symptoms. There is still no standard in the dosage and duration of the use of probiotics in CKD patients. Overall, the probiotic administration may have potential benefit in improving symptoms and quality of life, reducing inflammation, and delaying the progression of kidney failure. Further research studies using a larger sample size with longer follow-up durations and a greater focus on clinical outcomes—including survival—are warranted to elucidate the significant clinical impact of the use of probiotics in CKD patients.